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Abstract Gli1 is an established oncogene and its
expression in Estrogen Receptor (ER) a negative and triple
negative breast cancers is predictive of a poor prognosis;
however, the biological functions regulated by Gli1 in
breast cancer have not been extensively evaluated. Herein,
Gli1 was over-expressed or down-regulated (by RNA
interference and by expression of the repressor form of
Gli3) in the ERa negative, human breast cancer cell lines
MDA-MB-231 and SUM1315. Reduced expression of Gli1
in these two cell lines resulted in a decrease in migration
and invasion. Gli1 over-expression increased the migration
and invasion of MDA-MB-231 cells with a corresponding
increase in expression of MMP-11. Silencing MMP-11 in
MDA-MB-231 cells that over-expressed Gli1 abrogated the
Gli1-induced enhancement of migration and invasion.
Sustained suppression of Gli1 expression decreased growth
of MDA-MB-231 in vitro by increasing apoptosis and
decreasing proliferation. In addition, silencing of Gli1
reduced the numbers and sizes of pulmonary metastases of
MDA-MB-231 in an in vivo experimental metastasis assay.
In summary, Gli1 promotes the growth, survival, migra-
tion, invasion and metastasis of ERa negative breast can-
cer. Additionally, MMP-11 is up-regulated by Gli1 and
mediates the migration and invasion induced by Gli1 in
MDA-MB-231.
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Gli1 is a zinc finger transcription factor and a member of
the vertebrate Gli family. The Gli transcription factors,
which in addition to Gli1 include Gli2 and Gli3, are
effectors of the Hedgehog signaling pathway. The Gli
transcription factors coordinately regulate Gli-mediated
transcription [1]; however, Gli1 functions as the terminal
and critical activator of Gli-mediated transcription [2].
Although Gli1 was first identified through its role as a
transcriptional mediator of Hedgehog signaling, it is now
known that Gli1 expression and activity are also modulated
by other signaling pathways, including Transforming
Growth Factor b (TGFb), Ras/ERK, and Wnt [3–6].
Gli1 plays an important role in the initiation and pro-
gression of several types of cancer. Gli1 was first identified
by its amplification in human glioma [7]. Additionally,
Gli1 drives the development of cancers associated with
Gorlin’s syndrome, which include basal cell carcinomas,
medulloblastomas and rhabdomyosarcomas and result from
inappropriate activation of Hedgehog signaling by muta-
tions of pathway members [8]. Gli1 activity has also been
shown to promote the growth, migration, invasion and/or
metastasis of several other cancer types, including cancers
of the prostate and pancreas [9–11].
Several lines of evidence indicate that Gli1 contributes
to breast cancer development and progression. Conditional
expression of Gli1 under the regulation of the MMTV
promoter induces mammary carcinomas in transgenic
mice. These Gli1-induced carcinomas are Estrogen
Receptor (ER) a negative and have features reminiscent of
the basal subtype of human breast cancers [12]. Over-
expression of Gli1 in human breast cancer tissue and cell
lines is well-documented [13, 14]. In addition, Gli1
expression has been shown to be an indicator of a poor
prognosis in human breast cancers [14–16]. Our prior work
found that nuclear localization of Gli1 protein indicates a
poor prognosis in women with ERa negative and triple
negative breast cancers (i.e., those breast cancers lacking
ERa, Progesterone Receptor (PR) and amplification of
Her2/neu [17]), but not in those with ERa positive cancers
[16].
Although it has been shown that Gli1 predicts a poor
outcome in ERa negative and triple negative breast
cancers, the functions of Gli1 in these cancer types have
not been extensively studied. To examine the role of Gli1
in the progression of ERa negative breast cancers, we
studied whether modulation of Gli1 expression would
influence the migration, invasion and metastasis of cell
lines representative of ERa negative breast cancer. In
addition, we found that Gli1 up-regulates the expression of
the matrix metalloproteinase (MMP) MMP-11 in these
breast cancer cell lines and studied its contribution to Gli1-
induced migration and invasion. Herein, we provide evi-
dence that Gli1 promotes the migration, invasion, and
metastasis of ERa negative breast cancer.
Materials and methods
Cell lines and culture conditions
The MDA-MB-231 (231) breast cancer cell line was a gift
from Dr. Janet Price, MD Anderson Cancer Center
(Houston, TX), and was maintained in Dulbecco’s Modi-
fication of Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS). The SUM1315 cells were a
gift of Dr. Stephen Ethier, Karmanos Cancer Institute
(Detroit, MI), and maintained in Ham’s F-12 media sup-
plemented with 5% FBS, Insulin (10 lg/ml), and Epider-
mal Growth Factor (EGF) (20 ng/ml). MCF10A cells were
purchased from the American Type Culture Collection and
were maintained as previously described [18].
Production of viral supernatants and transduction
For expression of Gli1, the pLJD-HA-Gli1 retroviral con-
struct and its corresponding empty vector control were gifts
of Dr. Michael Ruppert [19]. Retroviral supernatants were
prepared from Bing cells, and 231 and MCF10A cells were
transduced as described previously [20]. After transduc-
tion, cells were mass selected with 500–700 lg/ml G418
for at least 2 weeks. For silencing Gli1 expression, len-
tiviral supernatants were prepared using the pLKO.1-puro
constructs containing shRNA targeting human Gli1
(TRCN0000020484, TRCN0000020488; Mission shRNA
plasmid DNA, Sigma-Aldrich, Inc.) or a non-targeting
control (NT) shRNA (Sigma-Aldrich, Inc.), as per the
manufacturer’s protocol. Transduction of 231 cells was
followed by mass selection in 20 lg/ml puromycin for at
least 3 days. For expression of Gli3R, the pLenti6/
U6-Gli3R lentiviral construct and its corresponding
vector control (pLenti6/U6-b-galactosidase) were gifts of
Dr. Bradley Yoder, University of Alabama at Birmingham
(Birmingham, AL). Lentiviral supernatants were prepared
from 293T cells, and 231 cells were transduced as descri-
bed above.
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Quantitative, reverse transcription PCR
RNA was extracted and subjected to DNase pretreatment
prior to cDNA synthesis (High-Capacity cDNA Reverse
Transcription kit, Applied Biosystems, Inc.). Primer and
probe sets for Gli1, MMP-11 and Ribosomal Protein Large 0
(RPLP0) were purchased from Applied Biosystems (Taq-
Man Gene Expression Assays-on-Demand, Hs00171790_
m1, Hs00968295_m1 and Hs99999902_m1, respectively).
Gene assays were performed using TaqMan Universal PCR
Master Mix (Applied Biosystems, Inc.). Fluorescent signal
data were collected by the Applied Biosystems Prism 7700
Sequence Detection System. RPLP0 was used as the internal
reference. Relative expression values were calculated using
the DDCT method.
Western blot analysis
For detection of Gli1 and cleaved poly (ADP-ribose)
polymerase (PARP), cells were lysed in RIPA lysis buffer
(50 mM Tris–HCl at pH 7.4, 2 mM dithiothreitol, 1%
Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl
fluoride, and 79 protease inhibitor cocktail (Roche Applied
Science)). Fifty micrograms of total protein was separated
on 4–15% gradient gels and transferred to nitrocellulose
membranes. The membranes were blocked with 5% dry
milk in 0.1% PBS-T for 1 h at room temperature, followed
by incubation with the following primary antibodies indi-
vidually at 4C overnight: a mouse monoclonal antibody to
HA (1:1,000 dilution, clone 16B12, Covance, Inc.), a rabbit
polyclonal antibody to Gli1 (1:2,500 dilution, a gift of Dr.
Michael Ruppert), a mouse monoclonal antibody to
cleaved PARP (1:1,000 dilution, Asp214, Cell Signaling
Technology), or a mouse monoclonal antibody to b-actin
(1:20,000 dilution, Sigma-Aldrich, Inc.). Secondary
detection was achieved with horseradish peroxidase
(HRP)-conjugated secondary antibodies (Biorad Labora-
tories) and chemiluminescent HRP substrate.
For detection of secreted MMP-11, 1.5 9 106 cells
were plated in a 60-mm dish. After attachment, the cells
were washed with cold phosphate buffered saline (PBS)
and 2.0 ml of serum-free DMEM was added to each plate.
Forty-eight hours later, the medium was collected and
centrifuged. The volume of medium loaded for protein
separation was normalized to the numbers of cells on
each plate at the time of media collection. A lysate of a
human cell line containing a high level of MMP-11
protein (ThermoScientific, MS-1035-PCL) was included
as a positive control. The remaining procedure was as
described above except that the membranes were incu-
bated with mouse monoclonal antibody to MMP-11
(1:500 dilution, clone SL3.05, Neomarkers/ThermoFisher
Scientific).
Transwell migration and invasion assays
For transwell migration assays, 1 9 105 cells were plated
in 24-well inserts (8-lm pore size, BD Biosciences). For
SUM1315 cells, cells were incubated in medium with 2%
FBS on the transwell inserts (i.e., top well), and medium
containing 5% FBS was placed in the bottom well. After
24 h, cells on the upper surface of the transwell filter were
removed, the filters were stained with hematoxylin and
eosin, and the number of cells that migrated through the
filters was counted in 5, random 2009 microscopic fields
per filter. For 231 cells, the same procedure was utilized
except that the top well contained DMEM medium sup-
plemented with 1% FBS and the bottom well contained
DMEM with 20% serum. For MCF10A cells, the top well
contained maintenance medium with 2% horse serum and
the bottom well contained maintenance medium with 5%
horse serum. For invasion assays, the same experimental
procedures as for transwell migration assays were used
except that the 24-well inserts were coated with growth
factor-reduced Matrigel (8-lm pore size, BD Biosciences).
Transfection of siRNA
To silence endogenous Gli1 expression in breast cancer
cell lines, 50 nM of 2 different siRNAs (Stealth RNAi
siRNA sets, Invitrogen) targeting Gli1 were transfected
using Lipofectamine RNAiMAX (Invitrogen) according to
the manufacturer’s protocols. Experiments were performed
48–72 h after transfection. To silence MMP-11 expression,
50 nM of a mixture of four different siRNAs (Smartpool
siRNA, Dharmacon) targeting MMP-11 were transfected
using Dharmafect transfection reagent (Dharmacon), as per
the manufacturer’s instructions. Experiments were per-
formed 72 h after transfection.
MTT assay
To measure cell growth, 5,000 cells per well were plated in
a 96 well plate, and MTT assay was performed using
CellTiter 96 Non-Radioactive Cell Proliferation Assay
(Promega), according to the manufacturer’s protocols.
Immunostaining for Ki-67
Cells on coverslips were fixed in 70% ethanol, dehydrated
in graded alcohols, permeabilized in acetone, rehydrated,
and treated with 3% hydrogen peroxide followed by
incubation with 3% goat serum. Cells were incubated with
a rabbit polyclonal antibody to Ki-67 (dilution 1:50,
Zymed/Invitrogen) for 1 h. Secondary detection was
accomplished using a streptavidin–biotin system, as pre-
viously described [21]. The percentage of Ki-67 labeled
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cells was determined after counting of cells in random,
2009 microscopic fields. A minimum of 500 cells was
counted.
Treatment with HPI-1
HPI-1 (Hedgehog Pathway Inhibitor-1) was purchased
from TimTec, Inc. and dissolved in dimethyl sulfoxide
(DMSO). Cells were treated with 5 and 10 lM HPI-1 in
DMEM containing 0.5% FBS. The medium was changed
every other day.
Experimental (tail vein) metastasis assay
231 cells were transduced to express shRNA targeting Gli1
(shGli1) or the NT control and maintained in selection
medium for 10 days. Adherent, viable cells were washed
and suspended in sterile Hank’s balanced salt solution.
2.5 9 105 cells were injected intravenously into the lateral
tail veins of 3 to 4-week-old, female, athymic mice (nu/nu-
Foxn1, Harlan Labs) to evaluate lung colonization. The
five groups of animals consisted of parental, non-trans-
duced cells and cells transduced with shGli1-1, shGli1-2, a
combination of shGli1-1/2, and the NT control. After
approximately 6 weeks, the mice were euthanized and the
lungs were removed and fixed in neutral-buffered formalin.
The number of surface metastases to the lungs was deter-
mined by examination under a dissecting microscope, and
the diameter of each metastasis was estimated with an
ocular micrometer. The volume of each metastasis was
calculated using the formula (4/3)pr3 [22].
Data analysis
Comparison of migration, invasion, optical density,
absorbance (MTT assay), Ki-67-labeling, and the numbers
and volumes of metastases was accomplished using the
unpaired t test with Welch’s correction or one-way
ANOVA with Tukey post-test. Only P values less than 0.05
were regarded as statistically significant.
Results
Over-expression of Gli1 promotes migration
and invasion of MDA-MB-231 breast cancer cells
To investigate the function of Gli1 in migration and inva-
sion of ERa negative breast cancers, Gli1 was over-
expressed and silenced in MDA-MB-231 (231) cells and
transwell migration and invasion assays were performed.
We utilized 231 cells for these experiments because they
are negative for ERa, PR and amplification of Her2/neu
[23], were derived from metastatic breast cancer [23], are
capable of metastasizing in xenograft models [24], and
express a high level of Gli1 relative to an epithelial cell line
derived from benign breast (i.e., MCF10A cells) (Supple-
mental Data, Fig. 1). HA-tagged Gli1 was expressed by
retroviral transduction followed by mass selection. Gli1
over-expression was confirmed by quantitative RT-PCR
(QRT) (Fig. 1a) and immunoblotting with anti-HA and
anti-Gli1 antibody (Fig. 1b). For transwell migration
assays, the number of Gli1 over-expressing 231 cells (231-
Gli1) and empty vector control cells (231-Vector) that
traversed the filters toward a serum gradient was counted
after 24 h. There was a significant enhancement of
migration by Gli1 overexpression (P = 0.002, t test)
(Fig. 1c). For transwell invasion assays, the number of
cells invading through basement membrane material
toward a serum gradient after 24 h was counted. Over-
expression of Gli1 also caused a significant increase in
invasion (P = 0.027, t test) (Fig. 1d). Growth of 231 cells
was not influenced by over-expression of Gli1 (Supple-
mental Data, Fig. 2a). Over-expression of Gli1 in a non-
cancerous breast cell line with a low level of Gli1
expression (Supplemental Data, Fig. 1), MCF10A, also
resulted in an increase in migration and invasion (Supple-
mental Data, Fig. 3).
Reduction of Gli1 expression and activity decreases
migration and invasion of ERa negative breast cancer
cells
To further demonstrate the role of Gli1 in migration and
invasion, Gli1 was silenced by siRNAs targeting Gli1 in
231 cells and transwell migration and invasion assays were
performed. Each siRNA achieved a 70–80% reduction in
Gli1 mRNA expression relative to a non-targeting siRNA
negative control (NT) (Fig. 2a). Silencing Gli1 expression
significantly decreased transwell migration (P \ 0.001,
ANOVA) and invasion (P \ 0.001, ANOVA) of the 231
cells (Fig. 2b, c). Cell growth was not affected by the short
term silencing of Gli1 by siRNA (Supplemental Data,
Fig. 2b).
Gli1 is a major activator of Gli-mediated transcription,
and it is also a direct target of Gli-mediated transcription in
most cell types [2]. Therefore, another approach to reduc-
ing Gli1 expression is to inhibit Gli-mediated transcription.
The repressor form of Gli3 (Gli3R) is an inhibitor of Gli-
mediated transcription. Gli3R is derived from full-length
Gli3 after proteolytic cleavage and lacks amino acids
C-terminal to the zinc finger domain [25]. To reduce Gli-
mediated transcription and Gli1 expression, Gli3R was
expressed in 231 cells (231-Gli3R) by lentiviral transduc-
tion. Overexpression of Gli3 in comparison to the vector
control (231-Vector) was confirmed by QRT (Fig. 2d).
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Correspondingly, expression of Gli1 was inhibited by
approximately 50% in 231-Gli3R cells (Fig. 2e), and
transwell migration and invasion of 231 cells was signifi-
cantly inhibited by expression of Gli3R (P = 0.039 and
P \ 0.001, t test, respectively) (Fig. 2f, g). Expression of
Gli3R for the time period required for the migration and
invasion assays had no effect on cell growth (Supplemental
Data, Fig. 2c) Therefore, by modulating expression of Gli1
via a variety of approaches, we have demonstrated that
Gli1 promotes the migration and invasion of 231 cells.
To extend this finding to another ERa negative breast
cancer cell line, Gli1 expression was also silenced in
SUM1315 cells using siRNA [23]. SUM1315 cells, like
231 cells, are ERa and PR negative and lack Her2/neu
amplification. They express Gli1 at a relatively high level
(Supplemental Data, Fig. 1), were derived from a meta-
static breast cancer [23], and are capable of metastasizing
in xenograft models [26]. Reduction of Gli1 expression in
SUM1315 by siRNA (Fig. 3a) significantly inhibited their
migration and invasion over a 24 h time period (P \ 0.001
for both, ANOVA) (Fig. 3b, c). Also similar to MDA-
MB-231 cells, short-term reduction in Gli1 expression had no
effect on cell growth (Supplemental Data, Fig. 2d). Taken
together, our data strongly support that Gli1 promotes the
migration and invasion of ERa negative breast cancer cells.
Gli1 regulates the expression of MMP-11 in ERa
negative breast cancer cells
To identify a potential down-stream mediator of Gli1 that
is responsible for the increase in migration and invasion
induced by Gli1, we quantified expression of MMP-11
mRNA and protein in 231-Gli1 and vector control cells.
MMP-11 was of particular interest because its expression
in breast cancer, either in cancer stroma or cancer epithelial
cells, is predictive of a poor prognosis [27, 28]. Addition-
ally, expression of MMP-11 in hepatocellular carcinoma
cell lines has been shown to promote their migration and
metastasis [29]; however, such a role for MMP-11 in breast
cancer has not been evaluated. MMP-11 mRNA was
upregulated by overexpression of Gli1 as assessed by QRT
(Fig. 4a). Immunoblotting for MMP-11 protein demon-
strated an increase in the secretion of cleaved, active
MMP-11 protein in the conditioned medium of 231-Gli1
cells compared to the conditioned medium of the vector
control cells (Fig. 4b). MMP-11 is processed intracellularly
to its enzymatically active form by a Golgi-associated
proteinase Furin, which cleaves the 65 kD MMP-11
zymogen to the 45 kD active form [30]. In some cell types,
the 45 kD active enzyme is the predominant secreted form
[30]; however, in other cell types, including 231 cells, both
Fig. 1 Over-expression of Gli1 enhanced migration and invasion of
MDA-MB-231 breast cancer epithelial cells. a HA-tagged Gli1 was
over-expressed by transduction (pLJD-HA-Gli1) of MDA-MB-231
(231-Gli1) cells followed by mass selection. Quantitative RT-PCR
(QRT) confirmed an increase in Gli1 mRNA expression in 231-Gli1
in comparison to the empty vector control cells (231-Vector). Over-
expression was confirmed prior to each experiment. b Western blot
analysis with anti-HA confirmed that HA-tagged Gli1 was over-
expressed in 231-Gli1 cells. Over-expression was also confirmed
using a polyclonal antibody that recognizes Gli1 (anti-Gli1). F9 cells
are a teratocarcinoma cell line with a high Gli1 expression and are a
positive control. b-actin was also probed for as a loading control.
c Transwell migration assays were performed for 24 h. The number of
cells that migrated through the transwell filter was increased in
231-Gli1 cells. Data were normalized to the vector control and are the
mean and standard error of three independent experiments performed
in triplicate (P = 0.002, t test). d Transwell invasion assays through
basement membrane material were performed for 24 h. The number
of cells that traversed the transwell filter was increased in 231-Gli1
cells. Data were normalized to the vector control and are the mean
and standard error of three independent experiments performed in
triplicate (P = 0.027, t test)
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the active enzyme and the inactive proenzyme are secreted
[30, 31]. Silencing Gli1 expression by siRNA decreased
MMP-11 expression in both 231 and SUM1315 cells as
quantified by QRT (Fig. 4c). Taken together, our data
indicate that MMP-11 is up-regulated by Gli1 in these ERa
negative breast cancer cell lines.
Gli1-induced migration and invasion is mediated
by MMP-11
To determine whether Gli1 enhances migration and inva-
sion by upregulating MMP-11 in 231 cells, we silenced
MMP-11 expression in 231-Gli1 cells using siRNA
(Fig. 4d) resulting in a reduction in secretion of MMP-11
protein in 231-Gli1 cells to a level similar to that in 231
cells without over-expression of Gli1 (Fig. 4e, f). Trans-
well migration and invasion assays were performed for
24 h. Migration and invasion of 231-Gli1 cells with
reduction of MMP-11 expression was decreased to the
level exhibited by 231-Vector cells (P = 0.006 and
P = 0.001, respectively, t test) (Fig. 4g, h). In addition,
silencing MMP-11 in 231 cells which do not over-express
Gli1 (231-vector) also resulted in a decrease in migration
and invasion (P \ 0.001 for both, t test) (Supplemental
Data, Fig. 4). Our data provide evidence that MMP-11 is
important for the migration and invasion of 231 cells, and
Fig. 2 Reduction of Gli1 expression significantly decreased migra-
tion and invasion of 231 cells. a QRT analysis demonstrated
decreased Gli1 mRNA expression in 231 cells 48 h after transfection
of 2 different siRNAs targeting Gli1 (siGli1-1, siGli1-2) compared
with a non-targeting siRNA control (NT). Decreased expression was
confirmed prior to each experiment. b and c Transwell migration
(b) and invasion (c) assays were performed for 24 h. Silencing Gli1
significantly decreased migration (P \ 0.001, ANOVA) and invasion
(P \ 0.001, ANOVA) of 231 cells in comparison to the NT control
cells. Data were normalized to the NT control and are the mean and
standard error of three independent experiments performed in
triplicate. d The repressor form of Gli3 (Gli3R) was expressed by
lentiviral transduction (pLenti6-Gli3R) of 231 cells (231-Gli3R). Gli3
overexpression in comparison to the vector control (231-Vector) was
confirmed by QRT analysis. Increased expression was confirmed prior
to each experiment. e Expression of Gli3R down-regulated Gli1
mRNA as measured by QRT in 231 cells. Data are the mean and
standard error of three independent experiments (P = 0.022, t test).
f and g Expression of Gli3R decreased migration (f) (P = 0.039,
t test) and invasion (g) (P \ 0.001, t test) of 231 cells (after 24 h) in
transwell migration and invasion assays as compared with the vector
control. Data are normalized to the vector control and are the mean
and standard error of three independent experiments performed in
triplicate
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its increase resulting from over-expression of Gli1 medi-
ates the promotion of migration and invasion induced by
Gli1.
Sustained inhibition of Gli1 expression and activity
reduces growth of MDA-MB-231 breast cancer cells
Analysis of the role of Gli1 in metastasis assays in vivo
requires sustained suppression of Gli1 expression or
activity over a 6 week period. We wanted to achieve a
sustained reduction in Gli1 expression by at least 70% to
maximize the phenotypic effect of Gli1 suppression. We
were unable to achieve this degree of sustained suppression
of Gli1 with either the siRNA or expression of Gli3R.
Therefore, we utilized shRNA, delivered by lentiviral
transduction, to achieve a sustained reduction in Gli1 at
2 weeks (western blot analysis, Fig. 5a) and after 1 month
(QRT, Fig. 5b). To compare the effect of Gli1 silencing by
shRNA with our prior results using siRNA and Gli3R, we
employed the MTT assay to measure cellular metabolic
activity as a surrogate for cell viability or growth. Similar
to the results with siRNA and Gli3R (Supplemental Data,
Fig. 2b and c), there was no significant inhibition of growth
5 days after transduction (Fig. 5c). However, with sus-
tained suppression of Gli1 expression for 10 days, growth
was markedly reduced (P \ 0.001, ANOVA) (Fig. 5c). To
determine whether this decrease in growth was a result of a
decrease in proliferation or increase in apoptosis, prolif-
eration was assessed by immunocytochemistry for Ki-67
and apoptosis was assessed by western blot analysis for
cleaved poly (ADP-ribose) polymerase (PARP) after sus-
tained reduction of Gli1. PARP is a nuclear enzyme
involved in DNA repair and is a substrate for Caspase 3
cleavage during apoptosis. PARP was increased in
231-shGli1 as compared to the NT control cells
(P \ 0.001, ANOVA) (Fig. 5d, e). There was also a sig-
nificant, but modest (12%), decrease in Ki-67 labeling with
Gli1 reduction (P = 0.02, t test) (Fig. 5f). Therefore, the
decrease in growth with sustained Gli1 suppression was a
result of increased apoptosis and, to some extent, decreased
proliferation.
To achieve long term inhibition of Gli1 by another
mechanism, we treated 231 cells continuously for 8 days
with the small molecular inhibitor of Gli-mediated tran-
scription, HPI-1. HPI-1 was identified as inhibitor of Gli-
mediated transcription by a high throughput screen in
NIH3T3 cells [32]. We confirmed the ability of HPI-1 to
inhibit Gli-mediated transcription by demonstrating a dose
dependent decrease in Gli1 expression after treatment with
HPI-1 for 48 h (Fig. 5g). Then, we treated 231 cells with
HPI-1 for 3 and 8 days and assessed cell growth by MTT
assay. After 3 days of treatment, there was no decrease in
cell growth (Fig. 5h), similar to the results seen with sup-
pression of Gli1 expression by shRNA, siRNA and Gli3R.
However, on day 8, cell growth was significantly reduced
(P \ 0.001, ANOVA) (Fig. 5h), similar to the effect
of sustained suppression of Gli1 expression by shRNA
(Fig. 5c).
Long-term silencing of Gli1 expression inhibits
experimental metastasis of MDA-MB-231 breast
cancer cells
To confirm that suppression of Gli1 expression by shRNA
also inhibits migration and invasion, similar to silencing by
siRNA, we performed migration and invasion assays, as
described above, 3 days after transduction with shRNA
targeting Gli1 (shGli1-1 and shGli1-2). Similar to the
siRNA experiments, there was a significant decrease in
migration and invasion of the 231 cells transduced with
shGli1 (231-shGli1) after 24 h (P \ 0.001 for migration
and invasion, ANOVA) (Fig. 6a, b). To provide direct
evidence that Gli1 is involved in the metastasis of ERa
negative breast cancer, experimental, tail-vein metastasis
Fig. 3 Reduction of Gli1 expression significantly impaired migration
and invasion of ERa negative SUM1315 breast cancer cells. a QRT
analysis demonstrated that endogenous Gli1 expression was reduced
in SUM1315 by transfection of two different siRNAs targeting Gli1
(siGli1-1, siGli1-2) in comparison to the non-targeting control (NT).
Decreased expression was confirmed prior to each experiment. b and
c Silencing Gli1 expression significantly inhibited migration
(b) (P \ 0.001, ANOVA) and invasion (c) (P \ 0.001, ANOVA) of
SUM1315 cells (after 24 h) in transwell migration and invasion
assays. Data are normalized to the NT control and are the mean and
standard error of three independent experiments performed in
duplicate or triplicate
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assays were conducted with the 231 cells transduced with
shGli1-1, shGli1-2 or a combination of shGli1-1 and
shGli1-2 and compared to the parental and non-targeting
(NT) controls. After transduction, the cells were grown in
selection medium for 12 days and subsequently injected
via the tail vein. Suppression of Gli1 expression in the
231-shGli1 cells was confirmed by QRT on the day prior to
injection (data not shown). Approximately 6 weeks after
Fig. 4 Expression of MMP11 is up-regulated by Gli1, and MMP11 is
important for Gli1-mediated migration and invasion of 231 cells.
a Over-expression of Gli1 resulted in an up-regulation of MMP11
mRNA in 231-Gli1 cells as measured by QRT. Data are the mean and
standard deviation (P \ 0.001, t test). b Western blot analysis
demonstrated elevated expression of the secreted, active form of
MMP-11 protein in conditioned media harvested from 231-Gli1 cells
in comparison to the conditioned medium from the same number of
vector control cells (231-Vector). The immunoblot demonstrated two
separate bands of *65 kD (latent proenzyme form) and *45 kD
(active form) of secreted MMP-11 protein. A cell lysate with a high
level of MMP11 (ThermoScientific) was included as a positive
control (Control). This immunoblot is representative of at least four
separate experiments. c QRT analysis demonstrated that silencing
Gli1 using siRNA reduces expression of MMP-11 mRNA in 231 and
SUM1315 cells in comparison to the non-targeting control (NT). The
data are the mean and standard error of two (231) or three (SUM1315)
experiments performed in triplicate (P \ 0.01 for each, ANOVA).
d QRT analysis indicated a reduced expression of MMP-11 after
transfection of siRNAs targeting MMP-11 (si-MMP11) in comparison
to a non-targeting siRNA control (NT) in 231-Gli1 cells. e and
f Western blot analysis of conditioned media from 231-Vector/NT,
231-Gli1/NT and 231-Gli1 with siRNA targeting MMP-11 (231-Gli1/
siMMP-11) demonstrated a reduction in secreted MMP-11 protein in
231-Gli1/siMMP-11 in comparison to 231-Gli1 to level that was
similar to 231-Vector/NT. This experiment was repeated three times
and densitometric representation of these experiments in f is normal-
ized to 231-Vector/NT (P = 0.034, t test). g and h Transwell
migration (g) and invasion (h) assays were performed after silencing
MMP-11 in 231-Gli1 cells. Silencing MMP11 significantly decreased
transwell migration (P = 0.006, t test) and invasion (P = 0.001,
t test) of 231-Gli1 cells (after 24 h). Data are normalized to the vector
control and are the mean and standard error of three independent
experiments performed in triplicate
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injection, the numbers and diameters of pulmonary
metastases were assessed by visual inspection of the
pleural surfaces under a dissecting microscope with the aid
of an ocular micrometer. The groups of mice injected with
shGli1 exhibited a marked reduction in the numbers of
metastases in comparison to the mice injected with the NT
Fig. 5 Sustained inhibition of Gli1 expression by shRNA or HPI-1
impaired growth of 231 cells. a Reduction in Gli1 expression 2 weeks
after transduction of shRNA targeting Gli1 (shGli1-1, shGli1-2) in
231 cells was verified by western blot analysis using a rabbit
polyclonal antibody (anti-Gli1). b-actin is a loading control. F9 cells
are a teratocarcinoma cell line with a very high expression of Gli1 and
are a positive control. b QRT analysis demonstrated that a reduction
in Gli1 mRNA was maintained for 1 month after transduction of
shGli1-1 and shGli1-2 in 231 cells in comparison to transduction of a
non-targeting shRNA control (NT). c Cell growth was measured at 5
and 10 days after transduction of shRNA targeting Gli1 in 231 cells
by MTT assay. Reduced expression of Gli1 for 5 days had little
impact on cell growth, whereas, after 10 days of inhibition of Gli1
expression there was a significant decrease in cell growth (P \ 0.001,
ANOVA). Data are the mean and standard error of three independent
experiments performed in triplicate. d To determine whether there
was an increase in apoptosis in 231 cells with sustained reduction in
Gli1 expression by shRNA (shGli1-1, shGli1-2), western blot analysis
for cleaved PARP was performed on day 9 after transduction with
shRNA targeting Gli1. The immunoblot was also probed for b-actin
as a loading control. There was an increase in cleaved PARP, as
indicated by an increase in the 89 kD cleavage product, in the shGli1-
1 and shGli1-2 cells in comparison to the NT control. e The mean
optical density of the bands corresponding to cleaved PARP on
immunoblots from three replicate, independent experiments was
greater in the shGli1 cells in comparison to the NT control cells
(P \ 0.001, ANOVA). The optical densities for PARP were normal-
ized to the optical densities of the corresponding bands for b-actin.
f 231 cells with sustained suppression of Gli1 expression (shGli1-1)
and the corresponding NT control cells were immunostained for Ki-
67 on day 9 after transduction. The percentages of Ki-67 labeled cells
(a minimum of 500 cells was counted) was significantly lower in the
shGli-1 cells in comparison to the NT control (P = 0.02, t test). Data
are the mean and standard error of three independent experiments.
g 231 cells were treated with HPI-1 (5 and 10 lM), an antagonist of
Gli-mediated transcription, for 48 h. Inhibition of Gli-mediated
transcription was indicated by a reduction in Gli1 mRNA, as
quantified by QRT, in treated cells in comparison to the vehicle
control. Data are the mean and standard deviation (P \ 0.01,
ANOVA). h MTT assay was performed on 231 cells treated with
HPI-1 for 3 and 8 days. HPI-1 did not decrease growth after 3 days of
treatment, but inhibited growth after 8 days of treatment (P \ 0.001,
ANOVA). Data are the mean and standard error of three independent
experiments performed in triplicate
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control cells (P \ 0.001, ANOVA) (Fig. 6c). An estimated
volume for each metastasis was calculated from the max-
imum diameter measured at the pleural surface. The mean
volumes of the metastases was significantly smaller in two
of the 231-shGli1 groups in comparison to the NT control
groups (P \ 0.001, t test) (Fig. 6d). However, in the
231-shGli1-1/2 group, there were three larger metastases
identified at the pulmonary surfaces that raised the mean
volume. Histologic analysis confirmed the decreased
numbers of metastases in the 231-shGli1 groups and con-
firmed that the metastases were indeed smaller in the
231-shGli1 groups compared to the NT and parental
Fig. 6 Reduction of Gli1 expression by shRNA inhibits migration,
invasion and metastasis. a and b Reduced expression of Gli1 by
different shRNA in 231 cells (shGli1-1, shGli1-2) markedly decreased
migration (a) (P \ 0.001, ANOVA) and invasion (b) (P \ 0.001,
ANOVA) after 24 h in comparison to NT control cells. Data are the
mean and standard error of three independent experiments performed
in triplicate. c Silencing Gli1 significantly inhibited the number of
metastasis of 231 cells to the lungs of female, athymic nude mice
(P \ 0.001, ANOVA) in an experimental metastasis assay. Parental
231 cells (n = 10 animals) or 231 cells transduced with the NT
control (n = 10), shGli1-1 (n = 6), shGli1-2 (n = 7) or a combina-
tion of the two shGli1 (n = 10) were injected into the tail-veins. The
numbers of metastases in the lungs were determined approximately
6 weeks after injection. d The volumes of each pulmonary metastasis
was also estimated and the mean volume of the metastases in the
lungs of the mice injected with shGli1-1 and shGli2-1 was smaller
than the metastases in the NT control group (P \ 0.001 for both
comparisons, t test), but this was not the case for the shGli1-1/2 group
because of several larger metastases identified at the pulmonary
surfaces in this group. e and f Histologic examination confirmed that
the metastases in the shGli1 groups were smaller than those in the NT
and parental controls. Representative metastases (outlined in black)
from the NT control (e) were larger than those in shGli1 groups
(shGli1-2 shown here) (f) in hematoxylin & eosin (H&E)-stained
histologic sections (9200 original magnification, scale bar = 50 lm).
g and h H&E-stained sections of the metastases (outlined in black)
identified at the pulmonary surfaces revealed that the metastatic cells
only coated the pleural surface and did not extend deeply into the
parenchyma in shGli1-1/2 mice (h), in contrast to those found at the
pulmonary surfaces of the NT (g) and parental control mice (9200
original magnification, scale bar = 50 lm)
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controls (Fig. 6e, f). Histologic analysis also revealed that
the ‘‘larger’’ metastases identified at the surfaces of the
lungs in the 231-shGli1-1/2 group only coated the pleural
surface and did not invade or extend deeply into the
underlying parenchyma, as was the case in the NT and
parental control groups (Fig. 6g, h). Therefore, even these
‘‘larger’’ metastases in the 231-shGli1-1/2 group were
relatively small in comparison to the controls.
Discussion
Our data indicate that Gli1 is important for the growth,
migration, invasion and metastasis of ERa negative breast
cancer. Our findings are supported by the work of others
also demonstrating that knockdown of Gli1 by RNA
interference in two ERa negative breast cancer cell lines,
MDA-MB-231 and SKBR3, reduced both cell growth and
invasion [33]. Silencing of Gli1 was also shown to inhibit
the metastasis of the MDA-MB-435 cancer cell line, but
whether this cell line represents ERa negative breast cancer
or melanoma is currently debated [34–36]. Therefore, our
data provide new evidence that Gli1 is important for the
metastasis of ERa negative breast cancer. In addition, we
report that Gli1 expression results in an increase in MMP-
11, which mediates the pro-migratory and pro-invasive
activities of Gli1 in the ERa negative MDA-MB-231 breast
cancer cell line.
Metastasis is a multi-step process that requires cancer
cells to detach from the main tumor, to migrate and invade
through stroma and intravasate, to survive in the circulatory
system and arrive at a secondary site, and to extravasate,
invade and grow at the secondary site. In the tail-vein
metastasis assay, only the later steps in this process are
tested, specifically survival in the circulatory system, and
extravasation, invasion and growth at the secondary site.
Our in vitro data indicating that Gli1 is important for cell
growth and survival, migration and invasion suggest that
Gli1 promotes metastasis by advancing several processes—
by promoting cell survival and growth in the lung and by
promoting migration and invasion through the vascular
wall and into the surrounding pulmonary parenchyma. The
smaller sizes of the metastases with Gli1 silencing indicate
the importance of Gli1 in promoting growth, while the
smaller number of metastases may result from inhibition of
the pro-survival effect of Gli1 or its role in promoting
migration and invasion from the vasculature and into the
lung parenchyma.
The cell lines included in this study, 231 and SUM1315,
are two of the few breast cancer cell lines that are capable
of metastasis in animal models. Expression of Gli1 mRNA
is higher in these two cancer cells (Supplemental Fig. 1)
than in MCF10A cells, which are derived from benign
breast and are non-tumorigenic and non-metastatic. While
Gli1 is relatively high in these metastatic lines, it is difficult
to directly correlate the level of endogenous Gli1 in a
cancer cell line and its relative migratory, invasive or
metastatic capability because many different genes and
complex molecular pathways contribute to their invasive
and metastatic phenotypes. Gli1 is one of many molecules
that regulate migration, invasion and metastasis. This is
underscored by the many different genes that have been
identified as being important in breast cancer metastasis,
including those that direct metastases to the lung and brain
[37, 38]. Of those 13 genes included in the gene expression
signature associated with metastasis to the lung and those
11 genes associated with metastasis to the bone [37, 38],
only one, CXCR4, has thus far been identified as a target of
Gli1-mediated transcription. However, several of the many
other genes that contribute to the metastasis of breast
cancer are known to be up-regulated by Gli1. These
include Osteopontin, Snail, Platelet-derived Growth Factor,
and MMP-9 [9, 19, 39–43].
In this study, we demonstrate that MMP-11 is also
up-regulated by Gli1 and that it contributes to the migration
and invasion induced by Gli1 in 231 cells. Therefore, a
reduction in MMP-11, and possibly other Gli1 targets,
inhibits migration and invasion relatively rapidly. Unlike
most MMP family members, MMP-11 does not cleave
major components of the extracellular matrix [44]. Several
potential substrates of MMP-11 have been identified and
include Collagen VI, Laminin Receptor, a1-Proteinase
Inhibitor, and Insulin Like Growth Factor (IGF) Binding
Protein 1 [30, 45–47]. MMP-11 was first identified from a
cDNA library of breast carcinoma tissues and its expres-
sion is up-regulated in invasive breast cancers compared to
ductal carcinoma in situ (DCIS) [48]. MMP-11 is expres-
sed at a high level in the fibroblastic stroma of breast
cancers, but is also expressed in the cancer epithelial cells
[27, 48–50]. Expression of MMP-11 in either the stromal or
epithelial compartment in breast cancer is predictive of a
poor disease outcome [27].
MMP-11 has been previously shown to contribute to the
migration and adhesion of a hepatocellular carcinoma cell
line, but the underlying molecular mechanism was not
elucidated [29]. A possible mechanism arises from the
observation that over-expression of MMP-11 in MCF7
cells resulted in activation of Erk1/2 and Akt [51]. Acti-
vated Akt regulates several proteins that are involved in
cell migration and invasion, either by direct phosphoryla-
tion of these proteins or by modulation of their upstream
regulators [52]. The Erk/MAPK pathway regulates differ-
ent processes involved in cell motility, including focal
adhesion disassembly and the activity of the Rho family of
small GTPases, which participate in cell migration and
invasion [53]. The mechanism through which MMP-11
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activates Erk1/2 and Akt has not been specifically eluci-
dated; however, it has been demonstrated that MMP-11 can
release extracellular IGF-1 bound to IGF Binding Protein
1, which is a substrate of MMP-11 [45]. IGF-1, by sig-
naling through the IGF-1 receptor can activate both Erk1/2
and Akt [54, 55]. Stimulation of IGF-1 signaling by MMP-
11 in MDA-MB-231 cells was shown to account for, at
least in part, an increased tumor take and growth of
xenografts of 231 cells overexpressing MMP-11 and to
enhance the expression of molecules involved in cell
migration and invasion [56].
Our present study also demonstrates that sustained inhi-
bition of Gli1 for 8–10 days, rather than a short-term inhi-
bition, is required to decrease the growth of 231 cells. This
finding suggests that Gli1 regulates the production of one or
more pro-survival signals, possibly secreted proteins, which
require several days after down-regulation of Gli1 to become
sufficiently diminished in quantity or activity that cell via-
bility can no longer be maintained. Alternatively, prolonged
culture may alter cellular function/homeostasis such that the
cells become more susceptible to the effects of decreased
Gli1 expression and activity.
Our data in the ERa negative and triple negative 231 and
SUM1315 cell lines also demonstrate the potential for
targeting Gli1 and the use of inhibitors of Gli-mediated
transcription in the treatment of ERa negative and triple
negative breast cancers. Triple negative breast cancers are
particularly aggressive and currently lack effective targeted
therapies [17]. Therefore, there is a critical need for the
development of new therapeutic strategies, such as target-
ing Gli1 via antagonists of Gli-mediated transcription, for
the treatment of breast cancer. Further work in both in vitro
and in vivo models of ERa negative and triple negative
breast cancer will be required to establish the efficacy of
targeting Gli1 using small molecule Gli1 antagonists.
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